Use of MHC II structural features in the design of vaccines for organ-specific autoimmune diseases

Current Pharmaceutical Design

Volumn 15, Issue 28, 2009, Pages 3262-3273

  Moustakas, Antonis K ^a   Papadopoulos, George K ^b  

^a IONIAN UNIVERSITY   (Greece)

^b Epirus Institute of Technology Arta   (Greece)

Author keywords

APL; Autoimmunity; HLA; MHC; Vaccines

Indexed keywords

AUTOANTIGEN; CD3 ANTIBODY; GLIADIN; GLUTAMATE DECARBOXYLASE 65; H2 ANTIGEN; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; HLA DR4 ANTIGEN; IA 2 ANTIGEN; INS B24 C32 33 PEPTIDE VACCINE; INSULIN; INSULIN B [15-23] PEPTIDE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE VACCINE; PROINSULIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELIAC DISEASE; CLINICAL TRIAL; CRYSTAL STRUCTURE; DISEASE PREDISPOSITION; DRUG BINDING SITE; DRUG DESIGN; DRUG DOSE REDUCTION; DRUG PROTEIN BINDING; DRUG SPECIFICITY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR BINDING; REGULATORY T LYMPHOCYTE; REVIEW; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE ACTIVATION; VACCINATION;

ANIMALS; AUTOIMMUNE DISEASES; DRUG DESIGN; GENES, MHC CLASS II; HLA ANTIGENS; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MODELS, MOLECULAR; RECEPTORS, ANTIGEN, T-CELL; VACCINES;

EID: 70449389546     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789105117     Document Type: Review

References (156)

1. McDevitt HO, Unanue ER. Autoimmune diabetes mellitus - much progress, but many challenges. Adv Immunol 2008; 100: 1-12.
2. Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 2006; 60: 12-21.
3. Icks A, Holl RW, Giani G. Economics in pediatric type 1 diabetes - results from recently published studies. Exp Clin Endocrinol Diabetes 2007; 115: 448-454 (Pubitemid 47234646)
4. Steinke JM, Mauer M. International diabetic nephropathy study group. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients. Pediatr Endocrinol Rev 2008; 5 (Suppl 4): 958-963
5. th ed. London, New York: Garland Science 2005; pp. 183-201
6. Bondinas GP, Moustakas AK, Papadopoulos GK. The spectrum of HLA-DQ and HLA-DR alleles, 2006: a listing correlating sequence and structure with function. Immunogenetics 2007; 59: 539-553
7. Jones EY, Fugger L, Strominger JL, Siebold C. MHC class II proteins and disease: a structural perspective. Nat Rev Immunol 2006; 6: 271-282
8. Lin L, Hungs M, Mignot E. Narcolepsy and the HLA region. J Neuroimmunol 2001; 117: 9-20.
9. Hakonarson H, Grant SF, Bradfield JP, Marchand L, Kim CE, Glessner JT, et al. A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature 2007; 448: 591-594 (Pubitemid 47206935)
10. Maier LM, Lowe CE, Cooper J, Downes K, Anderson DE, Severson C, et al. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin- 2 receptor production. PLoS Genet 2009; 5(1): e1000322.
11. Naluai AT, Nilsson S, Gudjónsdóttir AH, Louka AS, Ascher H, Ek J, et al. Genome-wide linkage analysis of Scandinavian affected sib-pairs supports presence of susceptibility loci for celiac disease on chromosomes 5 and 11. Eur J Hum Genet 2001; 9: 938-944 (Pubitemid 34149678)
12. Belz GT, Carbone FR, Heath WR. Cross-presentation of antigens by dendritic cells. Crit Rev Immunol 2002; 22: 439-448
13. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994; 265:106-109 (Pubitemid 24253184)
14. Douek DC, Altmann DM. T-cell apoptosis and differential human leucocyte antigen class II expression in human thymus. Immunology 2000; 99: 249-256
15. Suzuki E, Kobayashi Y, Kawano O, Endo K, Haneda H, Yukiue H, et al. Expression of AIRE in thymocytes and peripheral lymphocytes. Autoimmunity 2008; 41: 133-139
16. Matsuoka T, Tabata H, Matsushita S. Monocytes are differentially activated through HLA-DR, -DQ and -DP molecules via mitogenactivated protein kinases. J Immunol 2001; 166: 2202-2208 (Pubitemid 32173449)
17. Pugliese A, Brown D, Garza D, Murchison D, Zeller M, Redondo M, et al. Self-antigen-presenting cells expressing diabetes associated autoantigens exist in both thymus and peripheral lymphoid organs. J Clin Invest 2001; 107: 555-564 (Pubitemid 32205177)
18. Garcia CA, Prabakar KR, Diez J, Cao ZA, Allende G, Zeller M, et al. Dendritic cells in human thymus and periphery display a proinsulin epitope in a transcription-dependent, captureindependent fashion. J Immunol 2005; 175: 2111-2122 (Pubitemid 41113816)
19. Narendran P, Neale AM, Lee BH, Ngui K, Steptoe RJ, Morahan G, et al. Proinsulin is encoded by an RNA splice variant in human blood myeloid cells. Proc Natl Acad Sci USA 2006; 103: 16430-16435 (Pubitemid 44715213)
20. Sakaguchi S. Regulatory T cells: Meden Agan. Immunol Rev 2006; 212: 5-7.
21. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of Foxp3. Nat Genet 2001; 27: 20-21 (Pubitemid 32044513)
22. Baecher-Allan C, Wolf E, Hafler DA. MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol 2006; 176: 4622-4631
23. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead transcription factor FoxP3. Nat Immunol 2005; 6: 331-337
24. Uno S, Imagawa A, Okita K, Sayama K, Moriwaki M, Iwahashi H, et al. Macrophages and dendritic cells infiltrating islets with or without beta cells produce tumour necrosis factor-alpha in patients with recent-onset type 1 diabetes. Diabetologia 2007; 50: 596-601. (Pubitemid 46215503)
25. van de Wal Y, Kooy YM, van Veelen PA, Peña SA, Mearin LM, Molberg O, et al. Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin. Proc Natl Acad Sci USA 1998; 95: 10050-10054 (Pubitemid 28415292)
26. Molberg O, Kett K, Scott H, Thorsby E, Sollid LM, Lundin KE. Gliadin specific, HLA DQ2-restricted T cells are commonly found in small intestinal biopsies from coeliac disease patients, but not from controls. Scand J Immunol 1997; 46: 103-109 (Pubitemid 27298870)
27. Hafler DA, Benjamin DS, Burks J, Weiner HL. Myelin basic protein and proteolipid protein reactivity of brain- and cerebrospinal fluid-derived T cell clones in multiple sclerosis and postinfectious encephalomyelitis. J Immunol 1987; 139: 68-72. (Pubitemid 17091762)
28. Benvenuto R, Paroli M, Buttinelli C, Franco A, Barnaba V, Fieschi C, et al. Tumour necrosis factor-alpha synthesis by cerebrospinalfluid- derived T cell clones from patients with multiple sclerosis. Clin Exp Immunol 1991; 84: 97-102.
29. Stepniak D, Koning F. Celiac disease-sandwiched between innate and adaptive immunity. Hum Immunol 2006; 67: 460-468 (Pubitemid 43765609)
30. Steinman L. New targets for treatment of multiple sclerosis. J Neurol Sci 2008; 274: 1-4.
31. Apostolopoulos V, Yuriev E, Lazoura E, Yu M, Ramsland PA. MHC and MHC-like molecules: structural perspectives on the design of molecular vaccines. Hum Vaccine 2008; 4: 400-409
32. Lee KH, Wucherpfennig KW, Wiley DC. Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes. Nat Immunol 2001; 2: 501-507 (Pubitemid 33705851)
33. Siebold C, Hansen BE, Wyer JR, Harlos K, Esnouf RE, Svejgaard A, et al. Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy. Proc Natl Acad Sci USA 2004; 101: 1999-2004. (Pubitemid 38229004)
34. Kim C-Y, Quarsten H, Bergseng E, Khosla C, Sollid LM. Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci USA 2004; 101: 4175-4179 (Pubitemid 38405902)
35. Smith KJ, Pyrdol J, Gauthier L, Wiley DC, Wucherpfennig KW. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J Exp Med 1998; 188: 1511-1520 (Pubitemid 28489588)
36. Li Y, Li H, Martin R, Mariuzza RA. Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins. J Mol Biol 2000; 304: 177-188.
37. u. Immunity 2002; 17: 83-94.
38. g7 and autoimmune diabetes. Science 2000; 288: 505-511
39. Maynard J, Peterson K, Wilson DH, Adams EJ, Blondelle SE, Boulanger MJ, et al. Structure of an autoimmune T cell receptor complexed with class II peptide-MHC: insights into MHC bias and antigen specificity. Immunity 2005; 22: 81-92. (Pubitemid 40143453)
40. Hennecke J, Carfi A, Wiley DC. Structure of a covalentlystabilised complex of a human αβ T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1. EMBO J 2000; 19: 5611-5624
41. Hennecke J, Wiley DC Structure of a complex of the human αβ T cell receptor (TCR) HA1.7 influenza hemagglutinin peptide and major histocompatibility complex II molecule, HLA-DR4 (DRA1*0101 and DRB1*0401): insight into TCR cross-restriction and alloreactivity. J Exp Med 2002; 195: 571-581 (Pubitemid 34461502)
42. Hahn M, Nicholson MJ, Pyrdol J, Wucherpfennig KW. Unconventional topology of self-peptide-major histocompatibility complex binding of a human autoimmune T cell receptor. Nat Immunol 2005; 6: 490-496 (Pubitemid 41716762)
43. Li Y, Huang Y, Lue J, Quant JA, Martin R, Mariuzza RA. Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J 2005; 24: 2968-2979 (Pubitemid 41486334)
44. McBeth C, Seamons A, Pizarro JC, Fleishman SJ, Baker D, Kortemme T, et al. A new twist in TCR diversity revealed by a forbidden alphabeta TCR. J Mol Biol 2008; 375: 1306-1319
45. Rammensee HG, Friede T, Stevanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995; 41: 178-228. See also the updated listing on the web: http: //www.syfpeithi.de
46. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994; 368: 215-221 (Pubitemid 24108837)
47. Ghosh P, Amaya M, Mellins E, Wiley DC. The structure of an intermediate in class II MHC maturation: CLIP bound to HLADR3. Nature 1995; 378: 457-462
48. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 1997; 7: 473-481 (Pubitemid 27508699)
49. Jardetzky TS, Brown JH, Gorga JC, Stern LJ, Urban RG, Strominger JL, et al. Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides. Proc Natl Acad Sci USA 1996; 93: 734-738
50. van de Wal Y, Kooy MC, Drijfhout W, Amons R, Papadopoulos GK, et al. Peptide-binding features of the coeliac-diseaseassociated DQ(α1* 0501,β1*0201) molecule versus the nondisease- associated DQ(α1*0201,β1*0202) allele. Immunogenetics 1997; 46: 484-492
51. Ettinger RA, Kwok WW. A peptide binding motif for HLADQA1* 0102/DQB1*0602, the class II MHC molecule associated with dominant protection in insulin-dependent diabetes mellitus. J Immunol 1998; 160: 2365-2373
52. Zavala-Ruiz Z, Strug I, Anderson MW, Gorski J, Stern LJ. A polymorphic pocket at the P10 position contributes to peptide binding specificity in class II MHC proteins. Chem Biol 2004; 11: 1395-1402 (Pubitemid 39351376)
53. Palmer E, Naeher D. Affinity threshold for thymic selection through a T-cell receptor-co-receptor zipper. Nat Rev Immunol 2009; 9: 207-213
54. Daniels MA, Teixeiro E, Gill J, Hausmann B, Roubaty D, Holmberg K, et al. Thymic selection threshold defined by compartmentalization of Ras/MAPK signalling. Nature. 2006; 444: 724-729 (Pubitemid 44949596)
55. Viret C, He X, Janeway CA Jr. On the self-referential nature of naive MHC class II-restricted T cells. J Immunol 2000; 165: 6183-6192
56. Sasada T, Ghendler Y, Neveu JM, Lane WS, Reinherz EL. A naturally processed mitochondrial self-peptide in complex with thymic MHC molecules functions as a selecting ligand for a viralspecific T cell receptor. J Exp Med 2001; 194: 883-892 (Pubitemid 32953258)
57. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC. Structure of the complex between T-cell receptor, viral peptide and HLA-A2. Nature 1996; 384: 134-141 (Pubitemid 26386462)
58. Garcia KC, Degano M, Stanfield RL, Brunmark A, Jackson MR, Peterson PA, et al. An αβ T cell receptor structure at 2.5 Å and its orientation in the TCR-MHC complex. Science 1996; 274: 209-219 (Pubitemid 26353190)
59. Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 2006; 24: 419-466
60. Janeway CA Jr, Dianzani U, Portoles P, Rath S, Reich EP, Rojo J, et al. Cross-linking and conformational change in T-cell receptors: role in activation and in repertoire selection. Cold Spring Harb Symp Quant Biol 1989; 54 (Pt 2): 657-666 (Pubitemid 20190184)
61. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993; 364:33-39 (Pubitemid 23233452)
62. König R, Shen X, Germain RN. Involvement of both major histocompatibility complex class II alpha and beta chains indicates a role for ordered oligomerization in T cell activation. J Exp Med 1995; 182: 779-789
63. Lindstedt R, Monk N, Lombardi G, Lechler R. Amino acid substitutions in the putative MHC class II dimer of dimers' interface inhibit CD4+ T cell activation. J Immunol 2001; 166: 800-808 (Pubitemid 32060231)
64. Metz, DP, Farber DL, König R, Bottomly K. Regulation of memory CD4 T cell adhesion by CD4-MHC class II interaction. J Immunol 1997; 159: 2567-2573 (Pubitemid 127681273)
65. Lang HL, Jacobsen H, Ikemizu S, Andersson C, Harlos K, Madsen L, et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002; 3: 940-943 (Pubitemid 35154007)
66. Deng L, Langley RJ, Brown PH, Xu G, Teng L, Wang Q, et al. Structural basis for the recognition of mutant self by a tumorspecific, MHC class II-restricted T cell receptor. Nat Immunol. 2007; 8:398-408. (Pubitemid 46745415)
67. Li Y, Huang Y, Lue J, Quant JA, Martin R, Mariuzza RA. Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J 2005; 24: 2968-2979 (Pubitemid 41486334)
68. Archbold JK, Macdonald WA, Gras S, Ely LK, Miles JJ, Bell MJ, et al. Natural micropolymorphism in human leukocyte antigens provides a basis for genetic control of antigen recognition. J Exp Med 2009; 206: 209-219
69. Clements CS, Dunstone MA, Macdonald WA, McCluskey J, Rossjohn J. Specificity on a knife-edge: the alphabeta T cell receptor. Curr Opin Struct Biol 2006; 16: 787-795 (Pubitemid 44827723)
70. Nicholson MJ, Hahn M, Wucherpfennig KW. Unusual features of self-peptide/MHC binding by autoimmune T cell receptors. Immunity 2005; 23: 351-360 (Pubitemid 41443437)
71. Bach J-M, Otto H, Nepom GT, Jung G, Cohen H, Timsit J, et al. High affinity presentation of an autoantigenic peptide in type 1 diabetes by an HLA class II protein encoded in a haplotype protecting form disease. J Autoimmun 1997; 10: 375-386 (Pubitemid 27366143)
72. Reijonen H, Elliott JF, van Endert P, Nepom GT. Differential presentation of glutamic acid decarboxylase 65 (GAD65) T cell epitopes among HLA-DRB1*0401-positive individuals. J Immunol 1999; 163: 1674-1681 (Pubitemid 29352793)
73. Schulz RM, Hawa M, Leslie RDG, Sinigaglia F, Passini N, Rogge L, et al. Proliferative responses to selected peptides of IA-2 in identical twins discordant for type 1 diabetes. Diabetes/Metab Res Rev 2000; 16: 150-156 (Pubitemid 30410269)
74. Roep BO. T-cell responses to autoantigens in IDDM. The search for the Holy Grail. Diabetes 1996; 45: 1147-1156
75. Di Lorenzo TP, Peakman M, Roep BO. Systematic analysis of T cell epitopes in autoimmune diabetes. Clin Exp Immunol 2007; 148: 1-16.
76. Katsara M, Minigo G, Plebanski M, Apostolopoulos V. The good, the bad and the ugly: how altered peptide ligands modulate immunity. Expert Opin Biol Ther 2008; 8: 1873-1884
77. Madrenas J, Germain RN. Variant TCR ligands: new insights into the molecular basis of antigen-dependent signal transduction and Tcell activation. Semin Immunol 1996; 8: 83-101. (Pubitemid 26115971)
78. Thomson CT, Kalergis AM, Sacchettini JC, Nathenson SG. A structural difference limited to one residue of the antigenic peptide can profoundly alter the biological outcome of the TCRpeptide/ MHC class I interaction. J Immunol 2001; 166: 3994-3997
79. Masewicz SA, Papadopoulos GK, Swanson E, Moriarity L, Moustakas AK, Nepom GT. Modulation of T cell response to hGAD65 peptide epitopes. Tissue Antigens 2002; 59: 101-112 (Pubitemid 34620550)
80. Boots AM, Hubers H, Kouwijzer M, den Hoed-van Zandbrink L, Westrek-Esselink BM, van Doorn C, et al. Identification of an altered peptide ligand based on the endogenously presented, rheumatoid arthritis-associated, human cartilage glycoprotein- 39(263-275) epitope: an MHC anchor variant peptide for immune modulation. Arthritis Res Ther 2007; 9: R71-81.
81. Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005; 310: 850-855 [Erratum in: Science 2006; 311: 954]. (Pubitemid 41567343)
82. Ding Y-H, Baker BM, Garboczi DN, Biddison WE, Wiley DC. Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. Immunity 1999; 11: 45-56.
83. Baker BM, Cagnon SJ, Biddison WE, Wiley DC. Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC interphase: implications for TCR signaling. Immunity 2000; 13: 475-484
84. Xia J, Bergseng E, Fleckenstein B, Siegel M, Kim CY, Khosla C, et al. Cyclic and dimeric gluten peptide analogues inhibiting DQ2- mediated antigen presentation in celiac disease. Bioorg Med Chem 2007; 15: 6565-6573 (Pubitemid 47302312)
85. Jüse U, Fleckenstein B, Bergseng E, Sollid LM. Soluble HLA-DQ2 expressed in S2 cells copurifies with a high affinity insect cell derived protein. Immunogenetics 2009; 61: 81-89
86. Xia J, Siegel M, Bergseng E, Sollid LM, Khosla C. Inhibition of HLA-DQ2-mediated antigen presentation by analogues of a high affinity 33-residue peptide from alpha2-gliadin. J Am Chem Soc 2006; 128: 1859-1867 (Pubitemid 43277324)
87. Kel JM, Slütter B, Drijfhout JW, Koning F, Nagelkerken L. Mannosylated self-peptide inhibits the development of experimental autoimmune encephalomyelitis via expansion of nonencephalitogenic T cells. J Leukoc Biol 2008; 84: 182-190 (Pubitemid 351960293)
88. Sousa SF, Fernandes PA, Ramos MJ. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. Curr Med Chem 2008; 15: 1478-1492
89. Sibley RK, Sutherland DER, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest 1985; 53: 132-144
90. Serjeantson SW, Court J, Mackay IR, Matheson B, Rowley MJ, Tuomi T, et al. HLA-DQ genotypes are associated with auto immunity to glutamic acid decarboxylase in insulin-dependent diabetes mellitus patients. Hum Immunol 1993; 38: 97-104. (Pubitemid 24011923)
91. Akirav E, Kushner JA, Herold KC. Beta-cell mass and type 1 diabetes: going, going, gone? Diabetes 2008; 57: 2883-2888
92. Thorsby E, Rønningen KS. Particular HLA-DQ molecules play a dominant role in determining susceptibility or resistance to Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 371-377 (Pubitemid 23124038)
93. Platz P, Jakobsen BK, Morling N, Ryder LP, Svejgaard A, Thomsen M, et al. HLA-D and -DR antigens in genetic analysis of insulin dependent diabetes mellitus. Diabetologia 1981; 21: 108-115 (Pubitemid 11085847)
94. Ziegler AG, Hummel M, Schenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 1999; 48: 460-468 (Pubitemid 29106857)
95. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004; 114: 589-597 (Pubitemid 39572109)
96. Bottazzo GF, Dean BM, McNally JM, MacKay EH, Swift PG, Gamble DR. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 1985; 313: 353-360
97. Hanninen A, Jalkanen S, Salmi M, Toikkanen S, Nikolakaros G, Simell O. Macrophages, T cell receptor usage, and endothelial cell activation in the pancreas at the onset of insulin-dependent diabetes mellitus. J Clin Invest 1992; 90: 1901-1910
98. Foulis AL, Liddle CN, Farquharson MA, Richmond JA, Weir RS. The histopathology of the pancreas in Type I (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 1986; 29: 267-274
99. De Oliveira D, Harfouch-Hammoud E, Otto H, Papandreou NA, Stern LJ, Cohen H, et al. Structural analysis of two HLA-DR presented autoantigenic epitopes: crucial role of peripheral but not central peptide residues for T-cell receptor recognition. Mol Immunol 2000; 37: 813-825 (Pubitemid 32226377)
100. Arden SD, Roep BO, Neophytou PI, Usak EF, Duinkerken G, de Vries RRP, et al. Imogen 38: A novel 38-kD islet mitochondrial autoantigen recognised by T cells from a newly-diagnosed type 1 diabetic patient. J Clin Invest 1996; 97: 551-561 (Pubitemid 26039423)
101. Nepom GT, Lippolis JD, White FM, Masewicz S, Marto JA, Herman A, et al. Identification and modulation of a naturally processed T cell epitope from the diabetes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65) Proc Natl Acad Sci USA 2001; 98: 1763-1768 (Pubitemid 32165572)
102. Wicker LS, Chen S-L, Nepom GT, Elliott JF, Freed DC, Bansal A, et al. Naturally processed T cell epitopes from human Glutamic Acid Decarboxylase identified using mice transgenic for the type 1 diabetes-associated human MHC class II allele, DRB1*0401. J Clin Invest 1996; 98: 2597-2603 (Pubitemid 26415081)
103. Mallone R, Kochik SA, Reijonen H, Carson B, Ziegler SF, Kwok WW, et al. Functional avidity directs T-cell fate in autoreactive CD4+ T cells. Blood 2005; 106: 2798-2805 (Pubitemid 41510756)
104. Alleva DG, Crowe PD, Jin L, Kwok WW, Ling N, Gottschalk M, et al. A disease-associated cellular immune response in type 1 diabetes to an immunodominant epitope of insulin. J Clin Invest 2001; 107: 173-180 (Pubitemid 32096833)
105. Alleva DG, Gaur A, Jin L, Wegmann D, Gottlieb PA, Pahuja A, et al. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes 2002; 51: 2126-2134
106. Alleva DG, Maki RA, Putnam AL, Robinson JM, Kipnes MS, Dandona P, et al. Immunomodulation in type 1 diabetes by NBI- 6024, an altered peptide ligand of the insulin B epitope. Scand J Immunol 2006; 63: 59-69.
107. Papadopoulos GK, Moustakas AK, Eerligh P, Duinkerken G, Pinkse G, Koeleman BPC, et al. Identification of insulin B chain epitopes linked to type-1 diabetes susceptible DQ2 and -DQ8 cisand trans-dimers. Diabetologia 2005; 48 (Suppl 1): A98, abstract no. 257.
108. Kwok WW, Domeier ME, Raymond FC, Byers P, Nepom GT. Allele-specific motifs characterize HLA-DQ interactions with a diabetes associated peptide derived from glutamic acid decarboxylase. J Immunol 1996; 156: 2171-2177 (Pubitemid 26087447)
109. Levisetti MG, Suri A, Petzold SJ, Unanue ER. The insulin-specific T cells of nonobese diabetic mice recognize a weak MHC-binding segment in more than one form. J Immunol 2007; 178: 6051-6057 (Pubitemid 46717384)
110. Hausmann DH, Yu B, Hausmann S, Wucherpfennig KW. pHdependent peptide binding properties of the type I diabetesassociated Ag7 molecule: rapid release of CLIP at an endosomal pH. J Exp Med 1999; 189: 1723-1733 (Pubitemid 29272689)
111. Nakayama M, Beilke JN, Jasinski JM, Kobayashi M, Miao D, Li M, et al. Priming and effector dependence on insulin B: 9-23 peptide in NOD islet autoimmunity. J Clin Invest 2007; 117: 1835-1843 (Pubitemid 47036317)
112. Carrasco-Marin E, Shimizu J, Kanagawa O, Unanue ER. The class II MHC Ag7 molecules from non-obese diabetic mice are poor peptide binders. J Immunol 1996; 156: 450-458 (Pubitemid 26028902)
113. Münz C, Hofmann M, Yoshida K, Moustakas AK, Kikutani H, Stevanoviç S, et al. Peptide analysis, stability studies, and structure modeling explain contradictory peptide motifs and unique properties of the NOD mouse MHC II molecule H2-Ag7. Eur J Immunol 2002; 32: 2105-2116 (Pubitemid 34965873)
114. Latek RR, Suri A, Petzold SJ, Nelson CA, Kanagawa O, Unanue ER, et al. Structural basis of peptide binding and presentation by the type I diabetes-associated MHC class II molecule of NOD mice. Immunity 2000; 12: 699-710.
115. Godkin A, Friede T, Davenport M, Stevanovic S, Willis A, Jewell D, et al. Use of eluted peptide sequence data to identify the binding characteristics of peptides to the insulin-dependent diabetes susceptibility allele HLA-DQ8 (DQ 3.2). Int Immunol 1997; 9: 905-911 (Pubitemid 27231970)
116. Moustakas AK, Routsias J, Papadopoulos GK. Modelling of the MHC II allele I-A g7 of NOD mouse: pH-dependent changes in specificity at pockets 9 and 6 explain several of the unique properties of this molecule. Diabetologia 2000; 43: 609-624 (Pubitemid 30322079)
117. Pinkse GG, Tysma OH, Bergen CA, Kester MG, Ossendorp F, van Veelen PA, et al. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci USA 2005; 102: 18425-18430 (Pubitemid 43011242)
118. Hassainya Y, Garcia-Pons F, Kratzer R, Lindo V, Greer F, Lemonnier FA, et al. Identification of naturally processed HLA-A2 -restricted proinsulin epitopes by reverse immunology. Diabetes 2005; 54: 2053-2059 (Pubitemid 40911268)
119. Toma A, Haddouk S, Briand JP, Camoin L, Gahery H, Connan F, et al. Recognition of a subregion of human proinsulin by class Irestricted T cells in type 1 diabetic patients. Proc Natl Acad Sci USA 2005; 102: 10581-10586 (Pubitemid 41061597)
120. Martinuzzi E, Novelli G, Scotto M, Blancou P, Bach JM, Chaillous L, et al. The frequency and immunodominance of islet-specific CD8+ T-cell responses change after type 1 diabetes diagnosis and treatment. Diabetes 2008; 57: 1312-1320
121. Baker C, Petrich de Marquesini LG, Bishop AJ, Hedges AJ, Dayan CM, Wong FS. Human CD8 responses to a complete epitope set from preproinsulin: implications for approaches to epitope discovery. J Clin Immunol 2008; 28: 350-360
122. Skowera A, Ellis RJ, Varela-Calviño R, Arif S, Huang GC, Van- Krinks C, et al. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 2008; 118: 3390-3402
123. Wong FS, Karttunen J, Dumont C, Wen L, Visintin I, Pilip IM, et al. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat Med 1999; 5: 1026-1031 (Pubitemid 29439573)
124. Wong FS, Moustakas AK, Wen L, Papadopoulos GK, Janeway CA, Jr. Analysis of structure and function relationships of an autoantigenic peptide of insulin bound to H-2Kd that stimulates CD8 T cells in insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 2002; 99: 5551-5556
125. Martinez NR, Augstein P, Moustakas AK, Papadopoulos GK, Gregori S, Adorini L, et al. Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J Clin Invest 2003; 111: 1365-1371 (Pubitemid 36554707)
126. Wong FS, Siew LK, Scott G, Thomas IJ, Chapman S, Viret C, et al. Activation of insulin-reactive CD8 T cells for development of autoimmune diabetes. Diabetes 2009; 58: 1156-1164
127. Long SA, Walker MR, Rieck M, James E, Kwok WW, Sanda S, et al. Functional islet-specific Treg can be generated from CD4+CD25- T cells of healthy and type 1 diabetic subjects. Eur J Immunol 2009; 39: 612-620
128. You S, Candon S, Kuhn C, Bach JF, Chatenoud L. CD3 antibodies as unique tools to restore self-tolerance in established autoimmunity: their mode of action and clinical application in type 1 diabetes. Adv Immunol 2008; 100: 13-37.
129. Fenalti G, Law RH, Buckle AM, Langendorf C, Tuck K, Rosado CJ, et al. GABA production by glutamic acid decarboxylase is regulated by a dynamic catalytic loop. Nat Struct Mol Biol 2007; 14: 280-286 (Pubitemid 46608350)
130. Kim SJ, Jeong DG, Jeong SK, Yoon TS, Ryu SE. Crystal structure of the major diabetes autoantigen insulinoma-associated protein 2 reveals distinctive immune epitopes. Diabetes 2007; 56: 41-48
131. Fenalti G, Hampe CS, Arafat Y, Law RH, Banga JP, Mackay IR, et al. COOH-terminal clustering of autoantibody and T-cell determinants on the structure of GAD65 provide insights into the molecular basis of autoreactivity. Diabetes 2008; 57: 1293-1301
132. Stepniak D, Koning F. Enzymatic gluten detoxification: the proof of the pudding is in the eating. Trends Biotechnol 2006; 24: 433-434 (Pubitemid 44374782)
133. Sollid LM, Markussen G, Ek G, Gjerde H, Vartdal F, Thorsby E. Evidence for a primary association of celiac disease to a particular HLA-DQ α/β heterodimer. J Exp Med 1989; 169: 345-350 (Pubitemid 19035567)
134. Arentz-Hansen H, Körner R, Molberg O, Quarsten H, Vader W, Kooy YM, et al. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med 2000; 191: 603-612 (Pubitemid 30691413)
135. Arentz-Hansen H, McAdam SN, Molberg Ø, Fleckenstein B, Lundin KE, Jørgensen TJ, et al. Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues. Gastroenterology 2002; 123: 803-809
136. Vader W, Kooy Y, Van Veelen P, De Ru A, Harris D, Benckhuijsen W, et al. The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. Gastroenterology 2002; 122: 1729-1737 (Pubitemid 34651415)
137. Vader LW, de Ru A, van der Wal Y, Kooy YM, Benckhuijsen W, Mearin ML, et al. Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. J Exp Med 2002; 195: 643-649 (Pubitemid 34461509)
138. Vader W, Stepniak D, Kooy Y, Mearin L, Thompson A, van Rood JJ, et al. The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc Natl Acad Sci USA 2003; 100: 12390-12395 (Pubitemid 37271570)
139. Parrot I, Huang PC, Khosla C. Circular dichroism and nuclear magnetic resonance spectroscopic analysis of immunogenic gluten peptides and their analogs. J Biol Chem 2002; 277: 45572-45578 (Pubitemid 36159168)
140. Van de Wal Y, Kooy MC, van Veelen P, Peña S, Papadopoulos GK, Koning, F. Cutting Edge: Selective deamidation of gliadin by tissue transglutaminase strongly enhances gliadin-specific T-cell reactivity. J Immunol 1998; 161: 1585-1588 (Pubitemid 28387571)
141. Molberg O, Mcadam SN, Körner R, Quarsten H, Kristiansen C, Madsen L, et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nature Med 1998; 4: 713-717 [Erratum in: Nat Med 1998; 4: 974]. (Pubitemid 28274673)
142. Koelle DM, Johnson ML, Ekstrom AN, Byers P, Kwok WW. Preferential presentation of herpes simplex virus T-cell antigen by HLA DQA1*0501/ DQB1*0201 in comparison to HLA DQA1*0201/DQB1*0201. Hum Immunol 1997; 53: 195-205. (Pubitemid 27176475)
143. Vartdal F, Johansen BH, Friede T, Thorpe CJ, Stevanović S, Eriksen JE, et al. The peptide binding motif of the disease associated HLA-DQ (a1*0501/b1*0201) molecule. Eur J Immunol 1996; 26: 2764-2772 (Pubitemid 26364857)
144. Stepniak D, Wiesner M, de Ru AH, Moustakas AK, Papadopoulos GK, van Veelen PA, et al. Large scale characterization of natural ligands explains the unique binding properties of HLA-DQ2. J Immunol 2008; 180: 3268-3278
145. De Vivo G, Martin A, Trotta T, Gentile V. Role of transglutaminase- catalyzed reactions in the post-translational modifications of proteins responsible for immunological disorders. Inflamm Allergy Drug Targets 2008; 7: 24-29 (Pubitemid 351663642)
146. Pinkas DM, Strop P, Brunger AT, Khosla C. Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol 2007; 5: e327. (Pubitemid 351159708)
147. Koning F. A tertiary twist to the transglutaminase tale. PLoS Biol 2007; 5: e337.
148. Stepniak D, Spaenij-Dekking L, Mitea C, Moester M, de Ru A, Baak-Pablo R, et al. Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease. Am J Physiol Gastrointest Liver Physiol 2006; 291: G621-9. (Pubitemid 44511679)
149. Gjertsen HA, Sollid LM, Ek J, Thorsby E, Lundin KE. T cells from the peripheral blood of coeliac disease patients recognize gluten antigens when presented by HLA-DR, -DQ, or -DP molecules. Scand J Immunol 1994; 39: 567-574 (Pubitemid 24217149)
150. Hovhannisyan Z, Weiss A, Martin A, Wiesner M, Tollefsen S, Yoshida K, et al. The role of HLA-DQ8 beta57 polymorphism in the anti-gluten T-cell response in coeliac disease. Nature 2008; 456: 534-538 (Pubitemid 352759011)
151. Moustakas AK, van de Wal Y, Routsias J, Kooy YMC, van Veelen P, Drijfhout JW, et al. Structure of celiac disease-associated HLADQ8 and non-associated HLA-DQ9 alleles in complex with two disease-specific epitopes. Intl Immunol 2000; 12: 1157-1166 (Pubitemid 30616221)
152. Harkiolaki M, Holmes SL, Svendsen P, Gregersen JW, Jensen LT, McMahon R, et al. T cell-mediated autoimmune disease due to low-affinity crossreactivity to common microbial peptides. Immunity 2009; 30: 348-357
153. Beddoe T, Chen Z, Clements CS, Ely LK, Bushell SR, Vivian JP, et al. Antigen Ligation triggers a conformational change within the constant domain of the alphabeta T cell receptor. Immunity 2009; 30: 777-788.
154. Ferri S, Muratori L, Lenzi M, Granito A, Bianchi FB, Vergani D. HCV and autoimmunity. Curr Pharm Des 2008; 14(17): 1678-1685
155. Giovannetti A, Pierdominici M, Di Iorio A, Cianci R, Murdaca G, Puppo F, et al. Apoptosis in the homeostasis of the immune system and in human immune mediated diseases. Curr Pharm Des 2008; 14(3): 253-268
156. Rovere-Querini P, Brunelli S, Clementi E, Manfredi AA. Cell death: tipping the balance of autoimmunity and tissue repair. Curr Pharm Des 2008; 14(3): 269-277